Absci (ABSI) Net Margin (2020 - 2026)
Absci (ABSI) posted Net Margin of 13766.98% for Q1 2026, down 202.7% sequentially from 4548.0% in Q4 2025, and down 1153237.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Absci (ABSI) Net Margin (2020 - 2026) Analysis & Trends
Absci has reported Net Margin for 7 years, with the latest figure at 13766.98% in Q1 2026.
- Quarterly Net Margin fell 1153237.0% year-over-year to 13766.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6450.76% (down 421863.0% YoY) and the FY2025 annual result came in at 4113.68%, down 183962.0% from the prior year.
- Net Margin fell to 13766.98% in Q1 2026 per ABSI's latest filing, from 4548.0% in the prior quarter.
- Over five years, Net Margin peaked at 1237.66% in Q2 2023 and troughed at 13766.98% in Q1 2026.
- A 5-year average of 4754.04% and a median of 4358.35% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2026: Net Margin surged 855594 bps in 2022, then plunged 1153237 bps in 2026.
- Over 5 years, Net Margin stood at 5743.66% in 2022, then decreased by 21 bps to 6965.98% in 2023, then jumped by 37 bps to 4358.35% in 2024, then declined by 4 bps to 4548.0% in 2025, then plunged by 203 bps to 13766.98% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 13766.98%, 4548.0%, and 7594.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -10,443.40% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,443.40% |
| Mar 31, 2026 | -13,766.98% |
| Dec 31, 2025 | -4,548.00% |
| Sep 30, 2025 | -7,594.18% |
| Jun 30, 2025 | -5,154.97% |
| Mar 31, 2025 | -2,234.61% |
| Dec 31, 2024 | -4,358.35% |
| Sep 30, 2024 | -1,610.70% |
| Jun 30, 2024 | -1,948.82% |
| Mar 31, 2024 | -2,447.10% |
| Dec 31, 2023 | -6,965.98% |
| Sep 30, 2023 | -2,956.18% |
| Jun 30, 2023 | -1,237.66% |
| Mar 31, 2023 | -1,840.43% |
| Dec 31, 2022 | -1,250.55% |
| Sep 30, 2022 | -1,150.65% |
| Jun 30, 2022 | -2,862.28% |
| Mar 31, 2022 | -3,601.22% |
| Dec 31, 2021 | -1,733.20% |
| Sep 30, 2021 | -1,551.40% |